

Sector: IT & ITES

Results update

	Change
Reco: Buy	↔
CMP: Rs. 505	
Price Target: Rs. 650	↓
↑ Upgrade	↔ No change
↓ Downgrade	


Company details

Market cap:	Rs. 3,856 cr
52-week high/low:	Rs. 739/420
NSE volume: (No of shares)	1.1 lakh
BSE code:	533179
NSE code:	PERSISTENT
Sharekhan code:	PERSISTENT
Free float: (No of shares)	5.2 cr

Shareholding (%)

Promoters	31.9
FII	21.8
DII	25.3
Others	21.0

Price chart



Price performance

(%)	1m	3m	6m	12m
Absolute	-0.7	-29.3	-15.4	-18.8
Relative to Sensex	-6.1	-6.3	5.9	-1.6

Sharekhan Research, Bloomberg

Persistent Systems Limited (PSL) delivered a steady performance in a tough environment, with better-than-expected performance in both revenue and operating profitability. USD revenue came at \$127.1 million (ahead of our modest expectations), down by 1.8% q-o-q, attributed to significant 24.3% q-o-q decline in IP-led revenue due to weak seasonality and lower revenue re-seller business because of COVID-19 outbreak. However, the sharp decline in IP revenue was partially offset by 3.8% q-o-q growth in Technology Services Unit (TSU, 73.7% of total revenue), driven by strong 7% q-o-q growth in digital revenue. EBITDA margin improved by 41 bps q-o-q to 13.8% despite lower IP revenue and bad provisions in the wake of COVID-19, led by lower sales and marketing expenses, decline in purchase/royalty expenses, and rupee benefits (50 bps). The provision for impairment value of deposits in a troubled NBFC remained at Rs. 4.8 crore. Management remains cautiously optimistic on the demand environment, given some of its smaller clients are asking for discounts and slower demand environment in the wake of COVID-19. However, the company's TSU segment has been growing for the past four quarters at a CQGR of 4.5% under the new leadership. Management expects the growth momentum in this unit to continue on account of strong deal wins, new logo addition, and a healthy deal pipeline. Further, management continues to see significant opportunity from the salesforce business (grew by 13% q-o-q in Q4FY2020), given its presence in the healthcare and patient-care segment. Management expects margin to improve in FY2021E on account of lower sales and marketing expenses and completion of rebranding activities. We assume FY2021E is going to be a weak year, given anticipated material deterioration in the demand environment. However, growth is likely to recover in FY2022E once the situation normalises.

Key positives

- Strong 3.8% q-o-q/14.7% y-o-y growth in TSU revenue, led growth in BFSI, software, and hi-tech vertical
- EBITDA margin at 13.8%, ahead of our estimates
- Strong account mining in TSU – 3.9% and 4% q-o-q revenue growth in top and top 5 accounts (specific to TSU)

Key negatives

- IBM Alliance business revenue declined by 18.4% q-o-q

Our Call

Valuation – Reasonable valuation, retain Buy: We have fine-tuned our earnings estimates for FY2021E/FY2022E on account of better-than-expected performance in Q4FY2020 and decent commentary around TSU business, while headwinds in alliance business are expected to continue. We assume FY2021E is going to be a weak year, given anticipated material deterioration in the demand environment, and growth is likely to recover in FY2022E once the ongoing situation normalises. However, EBITDA margin is expected to improve in FY2021E on account of lower sales and marketing expenses and completion of re-branding exercise. At the current market price, the stock is trading at a reasonable valuation of 11x/9x its FY2021E/FY2022E earnings. Further, cash and cash equivalents account for 38% of its current market capitalisation. Hence, we retain our Buy rating on the stock with a revised price target (PT) of Rs. 650.

Key Risks

Any slowdown in non-Internet of Things (IoT) revenue/delay in product launches/stronger rupee and/or adverse cross-currency movements could affect earnings.

Valuation

	Rs cr				
Particulars	FY18	FY19	FY20	FY21E	FY22E
Revenue	3,033.7	3,365.9	3,565.8	3,626.3	3,995.0
OPM (%)	15.5	17.2	13.8	14.5	15.6
Adjusted PAT	323.1	351.7	340.3	356.1	414.5
% YoY growth	3.3	8.8	-3.2	4.6	16.4
Adjusted EPS (Rs.)	40.4	44.0	44.4	46.6	54.3
P/E (x)	12.5	11.5	11.4	10.8	9.3
P/B (x)	1.9	1.7	1.6	1.5	1.4
EV/EBITDA (x)	7.1	6.1	6.8	6.1	4.5
RoNW (%)	16.0	15.7	14.4	14.4	15.6
RoCE (%)	20.9	21.4	18.8	18.7	20.3

Source: Company; Sharekhan estimates

Steady quarter: PSL reported better-than-expected revenue and margin performance despite COVID-19 induced business disruption. USD revenue declined by 1.8% q-o-q to \$127.1 million, owing to sharp drop in IP-led revenue (down by 24.3% q-o-q) due to weak seasonality. However, the sharp decline in IP revenue was partially offset by 3.8% q-o-q growth in TSU (73.7% of the total revenue). Growth in TSU business during the quarter was driven by strong 7% q-o-q growth in digital revenue. Management highlighted that BFSI and software and hi-tech industry segments reported strong growth during the quarter. IP-led revenue during the quarter was impacted due to lower revenue in re-seller business due to COVID-19 outbreak in developed markets. EBITDA margin improved by 41 bps q-o-q to 13.8% despite lower IP revenue and bad provisions in the wake of COVID-19, led by lower sales and marketing expenses, decline in purchase/royalty expenses, and rupee benefits (50 bps). The provision for impairment value of deposits in a troubled NBFC remained at Rs. 4.8 crore. Net profit of Rs. 83.8 crore was 4.1% ahead of our estimates owing to higher profitability, partially offset by lower forex gain and higher tax provision.

Remains cautiously optimistic on the demand environment, focus on margin improvement: Management remains cautiously optimistic on the demand environment as some of its smaller clients are asking for discounts and some accommodations, slower demand environment in the view of COVID-19 and continued headwinds in IBM Alliance business. However, the company's TSU segment (73.7% of the total revenue) has been growing for the past four quarters at a CQGR of 4.5% despite a tough environment, under the new leadership team. The company continues to focus on BFSI and healthcare and life science verticals and expects growth momentum in these verticals to continue in the medium term on account of strong deal wins, new logo addition, and a healthy deal pipeline. Further, management highlighted that execution in the salesforce business has not impacted been yet and it continues to see significant opportunity from the salesforce business (grew by 13% q-o-q), given its presence in the healthcare and patient care segments. Management expects U-share recovery in the demand environment post COVID-19. Additionally, management expects revenue recovery in its alliance business in the coming quarters because of anticipated higher opportunities from Red Hat business of IBM and higher access to IBM's clients. Note the company has won a deal relating to the Red Hat business. Management focuses on margin improvement in FY2021E on account of lower sales and marketing expenses and completion of rebranding activities.

Key conference call highlights

- ♦ **IT services revenue delivered growth:** IT services revenue grew by 4.2% q-o-q, led by 5% q-o-q growth in ISV and 3.6% q-o-q growth in the enterprise business. Offshore linear revenue grew by 5.1% q-o-q, driven by 4.9% q-o-q growth in volume and 0.2% q-o-q growth in billing rate. Onsite linear revenue growth was driven by 3.1% q-o-q growth in billing, while volume growth was down by 0.2% q-o-q.
- ♦ **Strong growth in TSU:** Technology services revenue increased by 3.8% q-o-q to \$93.6 million, led by strong growth in BFSI (up 0.7% q-o-q/24.5% y-o-y) and followed by software and hi-tech business. Revenue growth in the healthcare and life science business remained flat. On service line perspective, salesforce services continued the growth momentum and delivered 13% q-o-q growth. Management sees strong traction around cloud-related offerings. The company has a strong pipeline in cloud and infrastructure business. In the TSU business, revenue from the top customer grew by 3.9% q-o-q, while revenue from the top 5, top 10 and top 20 customers grew by 4%, 2.3% and 3.8%, respectively, on sequential basis. This indicates secular growth in the top accounts in the TSU business. Growth in the TSU business was driven by cross-selling and gaining wallet share in existing customer accounts.
- ♦ **Segmental performance:** The BFSI vertical continued to deliver 0.7 q-o-q/24.5% y-o-y growth during Q4FY2020. The share of revenue from BFSI customers increased to 31.3% in Q4FY2020 from 30.5% in Q3FY2020 to 27.0% in Q4FY2019. The healthcare and lifesciences vertical's revenue growth remained flat on a sequential basis, while revenue grew by 5.2% y-o-y during the quarter. Revenue of the emerging vertical's declined by 4% q-o-q.
- ♦ **Alliance business:** Alliance business's revenue declined by 18.4% q-o-q in Q4FY2020 against a decline of 2% q-o-q in Q3FY2020. The recent acquisition of Red Hat by IBM provides a strong growth opportunity.
- ♦ **Decline in IP revenue:** IP-led revenue declined by 24.3% q-o-q, owing to seasonally weak quarter and lower growth in the re-seller business due to COVID-19 outbreak. Management highlighted that the re-seller business was impacted in March due to rapid spread of COVID-19 in developed markets. Note that a large portion of new license deal happens in March every year. With the outbreak of COVID-19, there is a setback in securing new license deal in its re-seller business.

- ♦ **Exposure to a troubled NBFC:** PSL provided an additional amount of Rs. 4.85 crore during Q4FY2020, taking the total provision to Rs. 43 crore (100% of the total exposure) towards its investments in bonds of a troubled NBFC.
- ♦ **Lower marketing expenses:** Marketing expenses declined by 1% q-o-q during the quarter due to few exits of employees at the end of the last quarter and adjustment in the cost structure.
- ♦ **Top clients' performance:** Revenue from the top client declined by 12.3% q-o-q. Revenue from the top-5 and top-10 clients declined by 3.7% and 4.1% q-o-q, respectively. Revenue from top 2-5 and top 2-10 increased by 5.2% and 1.8% q-o-q, respectively. The share of top customer reduced from 19.2% in Q4FY2020 from 21.5% in Q3FY2020 and 20.2% in Q4FY2019.
- ♦ **Client metrics:** The number of clients under the \$3 million+ category dropped by a couple to 20, while the number of clients under \$1 million+ bucket dropped by one on a q-o-q basis to 52.
- ♦ **Cash balance:** The company had cash and cash equivalents of Rs. 1,479.6 crore as of March 31, 2020, versus Rs. 1,377.9 crore as of December 31, 2019.

Results					Rs cr
Particulars	Q4Y20	Q4FY19	Q3FY20	Y-o-Y (%)	Q-o-Q (%)
Revenue (\$ mn)	127.1	118.3	129.4	7.4	-1.8
Net sales	926.4	831.9	922.7	11.4	0.4
Direct costs	613.0	525.5	615.7	16.7	-0.5
SG&A	185.7	179.8	183.6	3.3	1.2
EBITDA	127.7	126.6	123.4	0.9	3.4
Depreciation & amortisation	42.0	37.7	42.8	11.5	-1.9
EBIT	85.7	88.9	80.6	-3.6	6.3
Forex gain/(loss)	4.5	-5.9	10.2	-176.1	-56.4
Other income	22.9	28.3	23.2	-18.9	-1.0
PBT	113.0	111.3	114.0	1.6	-0.8
Tax provision	29.2	26.8	26.0	8.9	12.2
Net profit	83.8	84.5	87.9	-0.8	-4.7
EPS (Rs.)	11.0	10.6	11.5	3.6	-4.6
Margin (%)				BPS	BPS
EBITDA	13.8	15.2	13.4	-143	41
EBIT	9.2	10.7	8.7	-144	51
NPM	9.0	10.2	9.5	-111	-48

Source: Company; Sharekhan Research


Outlook

Social, mobility, cloud, analytics and IoT are estimated to account for more than 20% of the IT sector's revenue in 2020. As PSL is an early identifier of digital trends and has strong product development capabilities, we believe the company is well placed to capture a significant chunk of spends in digital technologies by clients going ahead. Though large exposure to its major clients (IBM) is a risk, the newly appointed CEO highlighted that the company would de-risk the IBM relationship by balancing the large client portfolio with focus on the industrial sector. Further, the company's leadership position in outsourced product development (OPD), elongated client relationships, and being an end-to-end service provider and partner in the clients' journey would help PSL to make most of the opportunity.

Valuation

We have fine-tuned our earnings estimates for FY2021E/FY2022E on account of better-than-expected performance in Q4FY2020 and decent commentary around the TSU business, while headwinds in the alliance business are expected to continue. We assume FY2021E is going to be a weak year, given anticipated material deterioration in the demand environment and growth likely to recover in FY2022E once the ongoing situation normalises. However, EBITDA margin is expected to improve in FY2021E on account of lower sales and marketing expenses and completion of re-branding exercise. At the current market price, the stock is trading at a reasonable valuation of 11x/9x its FY2021E/FY2022E earnings. Further, cash and cash equivalents account for 38% of its current market capitalisation. Hence, we retain our Buy rating on the stock with a revised PT of Rs. 650.

One-year forward P/E (x) band



Source: Sharekhan Research

About company

Incorporated in 1990, PSL is a global software company specialising in product and technology services. The company has organised itself into four business units - Services, Digital, Alliance and Accelerite. The company has proven expertise, strong presence in newer technologies and strength to improve its IP base. PSL focuses on developing IoT products and platforms, as it sees significant traction from industrial machinery, SmartCity, healthcare, and smart agriculture verticals. The company derives revenue from North America, Europe and Rest of the World.

Investment theme

Large corporates have been allocating higher budgets toward digital transformation initiatives and IT spends are moving from ISV to enterprise model. PSL has restructured its business and aligned its sales resources to capitalise the benefits from the clients' digital transformation journey. The alliance with IBM and investments in new-age technologies (IoT, Blockchain, artificial learning and machine learning) are expected to help the company capture opportunities from these spends.

Key Risks

1) Any slowdown in non-IoT revenue; 2) hostile regulatory development against current VISA regime; 3) delay in product launches and traction from clients in Accelerite; 4) stronger Indian rupee and/or adverse cross-currency movements; 5) margin dilution from M&A activity; and 6) high client concentration (around 23%+ revenue comes from IBM) could affect revenue growth.

Additional Data

Key management personnel

Dr. Anand Deshpande	Founder, Chairman and MD
Christopher O'Connor	Chief Executive Officer (CEO)
Sandeep Kalra	President: Technology Services
Sunil Sapre	Chief Financial Officer (CFO)
Mark Simpson	President, IBM Alliance

Source: Company Website

Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	HDFC Asset Management Company Limited	8.54
2	L&T Mutual Fund Trustee Limited	4.87
3	Norges Bank Investment Management	3.55
4	Government Pension Fund (Global)	3.51
5	PSPL ESOP management trust	3.22
6	UPADHYE NARASINHA	2.82
7	PPFAS Asset Management	2.70
8	Saif India V FII Holding Limited	2.68
9	Kotak Mahindra Asset Management Co	2.58
10	ICICI Prudential Asset Management	2.17

Source: Bloomberg

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

Sharekhan

by BNP PARIBAS

Know more about our products and services

For Private Circulation only

Disclaimer: This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst further certifies that neither he or its associates or his relatives has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Mr. Joby John Meledan; Tel: 022-61150000; email id: compliance@sharekhan.com;

For any queries or grievances kindly email igc@sharekhan.com or contact: myaccount@sharekhan.com

Registered Office: Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183;

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com; Investment in securities market are subject to market risks, read all the related documents carefully before investing.